MH PHARMA HOLDING : revenue, balance sheet and financial ratios

MH PHARMA HOLDING is a French company founded 23 years ago, specialized in the sector Fonds de placement et entités financières similaires. Based in CERISY-LA-FORET (50680), this company of category PME shows in 2022 a revenue of 1.1 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-05-09

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Financial history - MH PHARMA HOLDING (SIREN 443149026)
Indicator 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014
Revenue N/C N/C N/C 1 094 156 € N/C N/C N/C 791 437 € 793 793 € 785 075 € 782 254 € 801 365 €
Net income 203 539 € 55 482 € 113 211 € 99 411 € 67 954 € 65 289 € 49 329 € 19 227 € 14 202 € 15 416 € 21 201 € 29 242 €
EBITDA N/C N/C N/C 37 115 € N/C N/C N/C 13 694 € 17 579 € 19 580 € 26 223 € 25 368 €
Net margin N/C N/C N/C 9.1% N/C N/C N/C 2.4% 1.8% 2.0% 2.7% 3.6%

Revenue and income statement

In 2025, MH PHARMA HOLDING generates positive net income of 204 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2014-2025: 29 k€ -> 204 k€.

Net income (2025) ?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax

203 539 €

Loading income statement...

Chart evolution

Show :

Assets

Loading data...

Liabilities

Loading data...

Solvency and debt ratios

The debt ratio (= Financial debt / Equity x 100) stands at 53%. Debt remains under control: the company retains capacity to raise new debt if needed. Financial autonomy (= Equity / Total assets x 100) reaches 58%. This high autonomy means the company finances most of its assets through equity, a sign of strength.

Debt ratio (2025) ?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low
50-100% : Moderate
> 100% : High

53.123%

Financial autonomy (2025) ?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy
20-30% : Average
< 20% : Low

57.93%

Solvency indicators evolution
MH PHARMA HOLDING

Sector positioning

Debt ratio
53.12 2025
2023
2024
2025
Q1: 0.14
Med: 27.24
Q3: 146.28
Average -14 pts over 3 years

In 2025, the debt ratio of MH PHARMA HOLDING (53.12) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.

Financial autonomy
57.93% 2025
2023
2024
2025
Q1: 17.38%
Med: 54.75%
Q3: 87.41%
Good +11 pts over 3 years

In 2025, the financial autonomy of MH PHARMA HOLDING (57.9%) ranks above the median of the sector. This ratio represents the share of equity in total financing. This comfortable position offers an appreciable safety margin.

Liquidity ratios

The liquidity ratio (= Current assets / Current liabilities) stands at 559.55. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.

Liquidity ratio (2025) ?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good
1-1.5 : Fair
< 1 : Liquidity risk

559.549

Liquidity indicators evolution
MH PHARMA HOLDING

Sector positioning

Liquidity ratio
559.55 2025
2023
2024
2025
Q1: 159.67
Med: 1116.63
Q3: 6512.12
Average +8 pts over 3 years

In 2025, the liquidity ratio of MH PHARMA HOLDING (559.55) ranks below the median of the sector. This ratio measures the ability to cover short-term debt with current assets. An improvement would strengthen the competitive position.

Working capital requirement (WCR) and payment terms

Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments.

Operating WCR (2025) ?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released
Positive = financing needed

0 €

Customer credit (2025) ?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good
45-60j : Average
> 60j : Long

0 j

Supplier credit (2025) ?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow

0 j

Inventory turnover (2025) ?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover

0 j

WCR and payment terms evolution
MH PHARMA HOLDING

Positioning of MH PHARMA HOLDING in its sector

Comparison with sector Fonds de placement et entités financières similaires

Valuation estimate

Based on 170 transactions of similar company sales (all years), the value of MH PHARMA HOLDING is estimated at 2 110 048 € (range 1 307 923€ - 3 281 789€). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.

Estimated enterprise value 2025
170 transactions
1307k€ 2110k€ 3281k€
2 110 048 € Range: 1 307 923€ - 3 281 789€
NAF 5 all-time

Valuation method used

Net Income Multiple
203 539 € × 10.4x = 2 110 048 €
Range: 1 307 923€ - 3 281 790€

Only this financial indicator is available for this company.

Valuation evolution

How is this estimate calculated?

This estimate is based on the analysis of 170 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.

  • EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
  • Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
  • Net Income Multiple: Relevant for mature companies with stable results.

This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).

Similar companies (Fonds de placement et entités financières similaires)

Compare MH PHARMA HOLDING with other companies in the same sector:

Voir toutes les statistiques du secteur Fonds de placement et entités financières similaires

Frequently asked questions about MH PHARMA HOLDING

What is the revenue of MH PHARMA HOLDING ?

The revenue of MH PHARMA HOLDING in 2022 is 1.1 M€.

Is MH PHARMA HOLDING profitable?

Yes, MH PHARMA HOLDING generated a net profit of 204 k€ in 2025.

Where is the headquarters of MH PHARMA HOLDING ?

The headquarters of MH PHARMA HOLDING is located in CERISY-LA-FORET (50680), in the department Manche.

Where to find the tax return of MH PHARMA HOLDING ?

The tax return of MH PHARMA HOLDING is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does MH PHARMA HOLDING operate?

MH PHARMA HOLDING operates in the sector Fonds de placement et entités financières similaires (NAF code 64.30Z). See the 'Sector positioning' section above to compare the company with its competitors.